[ad_1]
The government announced that it has signed a contract to purchase a COVID-19 vaccine with global pharmaceutical companies Janssen (Johnson & Johnson) and Pfizer.
On the 24th, the government said: “Along with the 20 million AstraZeneca contracts signed previously, 20 million from Pfizer and 6 million from Janssen will be supplied.” “In the case of Janssen, 2 million more than the original 4 million We have signed a contract with quantity,” he announced. The Janssen vaccine will be introduced in the second quarter of next year and the Pfizer vaccine will be introduced in the third quarter of next year. .
Consequently, 20 million sessions (for 10 million people) of ‘Covax Facility’, an international project for the joint purchase and distribution of vaccines, and 66 million sessions (for 36 million people) of negotiations of individual pharmaceutical companies A total of 86 million (4,600 people) are introduced into Korea. It looks like he can get a vaccine for 10,000 people. According to the government, in the case of modders or 10 million people, negotiations are underway with the goal of a contract in January next year.
Prime Minister Jeong Sye-gyun said: “We have signed a contract for 10 million Pfizer vaccines at the Security and Disaster Countermeasures Headquarters for Corona 19 chaired at the Seoul government office, and it will start in the third quarter of next year. “. We are mobilizing in total, ”he said. Yang Dong-gyo, head of the Office of Prevention and Medical Safety at the Centers for Disease Control and Prevention, said: “There is no problem vaccinating 60-70% of people, as 86 million are being prepared dose “. For the matter, we are preparing to complete the vaccination before the epidemic period ”, he said.
[정슬기 기자 / 윤지원 기자]Biden’s Pfizer vaccine will be introduced in the third quarter of next year …
Introduction of the vaccine and vaccination period.
Janssen still in phase 3 clinical trial
Antibody formation with a single inoculation
Pfizer has the best prevention effect
The government only reveals plans for its introduction in the third quarter
Is there a problem with an FDA approved vaccine?
After foreign safety / vaccination analysis
Be vaccinated according to national procedures.
60 ~ 70% of citizens must be vaccinated
The maintenance period for vaccine antibodies has not been disclosed.
On the afternoon of the 24th, a banner is hung at the entrance of Seongsan Ilchulbong Peak, Seongsan-eup, Seogwipo-si, Jeju-do, to control access to the Corona 19 prevention trail. The access control period It is from December 24 to January 3 of next year. [사진 = 연합뉴스]Since the spread of Corona 19 in Korea is rarely detected, the Korean government urgently announced that it has insured up to 46 million corona 19 vaccines abroad. However, even if a vaccine that has been signed into a purchase contract as planned by the government is introduced in Korea, the vaccination point is still in February next year. Questions and answers about the Janssen vaccine, which was signed this time, and plans to secure the vaccine in the future, were summarized in Questions and Answers.
Q. When is the introduction of the vaccine and vaccination?
A. The Janssen vaccine will be introduced in the second quarter of next year and the Pfizer vaccine will be introduced in the third quarter of next year. The first AstraZeneca vaccine, which completed the purchase contract, is expected to be introduced in the first quarter of next year, but it is not yet clear how much volume will come in. The government said the AstraZeneca vaccine would be administered starting next February. The Janssen vaccine is scheduled to begin inoculation with introduction in the second trimester. The volume of the contract does not arrive at once. Regarding the initial volume, the government said that it was not possible to disclose in detail due to the confidentiality agreement. The Modena vaccine is being negotiated with the goal of signing a contract in January next year.
Q. What are the characteristics of the Janssen vaccine?
A. The biggest advantage of Janssen is that the storage and distribution conditions are not demanding. Janssen vaccine can be stored for 6 months at 2-8 degrees. In particular, unlike the Pfizer vaccine, which requires two doses, only one dose of the Janssen vaccine produces antibodies. The cost for a single dose of Janssen’s vaccine is $ 10 (about 1,900 won). The problem is that the Janssen vaccine, like the AstraZeneca vaccine scheduled to be inoculated in February next year, has not been approved by the US Food and Drug Administration (FDA). Unlike the Pfizer vaccine, which has already been vaccinated in the US and other countries, starting with the UK, the Janssen vaccine is expected to complete phase 3 clinical trials in the first quarter of next year. As clinical results have not been disclosed, safety is not guaranteed. Previously, the Janssen vaccine was once discontinued in Brazil in October because an unknown illness occurred in a patient who received the vaccine. Janssen plans to apply for emergency use approval from the US FDA in January next year.
Q. Are there any side effects of vaccination abroad?
A. The Pfizer vaccine, which is the most vaccinated in the world, requires two doses and has the highest preventive effect at 95%. The UK and the US started vaccination this month and some allergic reactions have been reported. Also, since its efficiency stays around -70 degrees Celsius, it is difficult to manage because you have to establish a cryogenic state storage and distribution system. The Modena vaccine also requires two doses and the preventive effect is 94.1%. It should be distributed at -20 degrees Celsius.
Q. Are there any problems with vaccines not approved by the FDA?
A. Quarantine authorities are in a position to ensure that vaccinations are carried out safely after sufficiently verifying the internal situation of Corona 19, the status of foreign vaccines and adverse reactions, etc., along with the safety assessment and effectiveness in accordance with the procedures of the Ministry of Food and Drug Safety. Because it follows national procedure, it will proceed with the vaccination regardless of whether it has been approved by the FDA. The Food and Drug Administration announced that Pfizer on the 18th and Janssen on the 22nd requested a preliminary review. AstraZeneca requested a preliminary review of the non-clinical data on October 6.
Q. Who is the first target of vaccination?
A. The government is screening 36 million people, including the elderly, residents of collective facilities and patients with chronic illnesses, such as the ‘Crown Vulnerable Class 19’ and health workers, such as the ‘staff of essential social services’. Socially essential service personnel are workers in medical institutions, primary quarantine first responders, police and fire officials, workers in nursing and home welfare facilities, and military personnel. The Vaccination Advisory Committee (ACIP), an advisory body to the Centers for Disease Control and Prevention (CDC) related to Pfizer vaccines, selected healthcare workers and nursing home residents as priority targets. The following are seniors 75 years and older and workers in essential industries such as police, firefighters, prison guards, supermarket clerks, and teachers. Children, adolescents and pregnant women are expected to be excluded from priority vaccination because the results of the clinical trial of the COVID-19 vaccine are still insufficient.
Q. Is population immunity possible in different vaccines?
A. The immunity of the population and the type of vaccine do not matter. Regardless of the vaccine given, if 60 to 70% of people are vaccinated and antibodies are formed, it can develop into herd immunity.
The quarantine authorities said that there would be no problem with the immunity formation of the population with the number of insured vaccines. The government is in a position to ensure that people who are eligible for vaccination can finish vaccination before November, the period of the influenza epidemic next year.
[김덕식 기자 / 정슬기 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
